Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1 by Bouitbir, Jamal et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
Atherosclerosis
Opposite effects of statins on mitochondria
of cardiac and skeletal muscles: a ‘mitohormesis’
mechanism involving reactive oxygen species
and PGC-1
Jamal Bouitbir1,2, Anne-Laure Charles1,2, Andoni Echaniz-Laguna 3, Michel Kindo1,4,
Fre´de´ric Daussin1,2, Johan Auwerx5, Franc¸ois Piquard1,2, Bernard Geny1,2, and
Joffrey Zoll1,2*
1Faculty of Medicine, University of Strasbourg, Faculty of medicine, EA 3072, France; 2Physiology and Functional Explorations Department, CHRU of Strasbourg, New Civil Hospital,
BP 426, 67091, Strasbourg, France; 3Neurology Department, New Civil Hospital, Strasbourg, France; 4Cardiac Surgery Department, New Civil Hospital, Strasbourg, France; and
5Institute of Bioengineering, Ecole Polytechnique Fe´de´rale de Lausanne (EPFL), Lausanne, Switzerland
Received 19 November 2010; revised 20 April 2011; accepted 23 June 2011; online publish-ahead-of-print 20 July 2011
See page 1299 for the editorial comment on this article (doi:10.1093/eurheartj/ehr287)
Aims Statins protect against cardiovascular-related mortality but induce skeletal muscle toxicity. To investigate mechanisms
of statins, we tested the hypothesis that statins optimized cardiac mitochondrial function but impaired vulnerable
skeletal muscle by inducing different level of reactive oxygen species (ROS).
Methods
and results
In atrium of patients treated with statins, ROS production was decreased and oxidative capacities were enhanced
together with an extensive augmentation of mRNAs expression of peroxisome proliferator-activated receptor
gamma co-activator (PGC-1) family. However, in deltoid biopsies from patients with statin-induced muscular myopathy,
oxidative capacities were decreased together with ROS increase and a collapse of PGC-1 mRNA expression. Several
animal and cell culture experiments were conducted and showed by using ROS scavengers that ROS production was
the triggering factor responsible of atorvastatin-induced activation of mitochondrial biogenesis pathway and improve-
ment of antioxidant capacities in heart. Conversely, in skeletal muscle, the large augmentation of ROS production fol-
lowing treatment induced mitochondrial impairments, and reduced mitochondrial biogenesis mechanisms. Quercetin,
an antioxidant molecule, was able to counteract skeletal muscle deleterious effects of atorvastatin in rat.
Conclusion Our findings identify statins as a new activating factor of cardiac mitochondrial biogenesis and antioxidant capacities,
and suggest the importance of ROS/PGC-1 signalling pathway as a key element in regulation of mitochondrial function
in cardiac as well as skeletal muscles.
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Introduction
Statins (HMG-CoA reductase inhibitors) are the most frequently
prescribed medication in developed countries. They impair choles-
terol synthesis by inhibiting the synthesis of mevalonate, the rate-
limiting step in cholesterol biosynthetic pathway.1 Statins reduce
cardiovascular-related morbidity and mortality in patients with or
without coronary artery disease.2 It is widely accepted that statins
have pleiotropic beneficial effects at the cardiovascular level,3,4 par-
ticularly by enhancing the bioavailability of vascular NOS-derived
NO. Statins are generally well tolerated but can provoke a variety
of skeletal muscle associated, dose-dependant adverse reactions,
ranging from muscle pain to rhabdomyolysis that sometimes
persist several months after treatment withdrawal.5
Little is known about the molecular mechanisms by which
statins protect against cardiovascular-related morbidity but lead
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to skeletal muscle injury. In vivo studies documenting the effects of
statins on cardiac mitochondria are rare. In cardiomyocytes, Jones
et al.6 showed that simvastatin protected mitochondria from oxi-
dative stress. At the skeletal muscle level, in vitro investigations
have shown that simvastatin inhibited complex I of the mitochon-
drial electron transport chain.7 Moreover, several studies have
shown that mitochondrial impairments could be largely implicated
in the deleterious effects of statins.8,9
The role of mitochondria also extends far beyond energy pro-
duction,10 as they are important generators of reactive oxygen
species (ROS), which can act either as second messengers or as
a source of cellular damage, depending of the ROS production
level.11– 14 As a vital organ rich in mitochondria and with high
oxygen use, the heart is prone to oxidative damage. Furthermore,
metabolic and apoptotic pathway converge on mitochondria and
are both recognized as playing a major role in disease.15,16 It is
thus crucial to clearly characterize the mechanisms of
statin-associated mitochondrial modifications in different muscle
phenotypes.7,9,17,18
Advances in molecular biology have started to elucidate the tran-
scriptional events governing mitochondrial biogenesis. Peroxisome
proliferator-activated receptor gamma co-activator (PGC-1a) is
considered to be the major regulator of mitochondrial biogenesis.19
Interestingly, a new concept proposed that mitochondrial biogenesis
could be triggered by low doses of mitochondrial ROS to counteract
stressor challenges and to re-establish homeostasis. This concept
called mitochondrial hormesis or ‘mitohormesis’.13,20,21
However, the effects of statin treatment on the molecular
events controlling mitochondrial biogenesis have never been inves-
tigated according to the muscular metabolic phenotype, although
this may be a potential mechanism to control muscular mitochon-
drial function.
In the present study, we investigated the effects of statin treat-
ment on ROS production-induced mitochondrial biogenesis in
cardiac and skeletal muscles in humans, animals and cell
culture models. We demonstrated that statin treatment pro-
duced a low amount of ROS in cardiac muscle, which activated
mechanisms of mitochondrial biogenesis and the antioxidant
system via the PGC-1 signalling pathway. In contrast, in patients
with statin-induced myopathy as well as in skeletal muscle of
rats, a large amount of ROS following statin treatment down-
regulated mitochondrial biogenesis, and triggered deleterious
effects on mitochondrial function. Altogether, our results
demonstrated that statins acted via a ‘mitohormesis’ mechanism
in order to activate mitochondrial biogenesis and protect cardiac
metabolism.
Methods
Surgical procedure and human atrial
appendage sampling
All surgeries were performed through a full median sternotomy
incision and under cardiopulmonary bypass. Heparin (300 U/kg,
i.v.) was given. Arterial cannulation was performed via the distal
ascending aorta. Single venous cannulation with a cavoatrial
cannula was introduced via the right atrial appendage. The right
atrial appendage was systematically harvested allowing the venous
cannulation before starting cardiopulmonary bypass and was
immediately rinsed in ice-cold Buffer S solution.22 Excess buffer
was removed and subendocardial myocardial layer was harvested.
A sample was immediately frozen in liquid nitrogen. Right atrial
biopsies were obtained from six patients treated with statins and
eight patients not treated with statins (Supplementary material
online, Table S1). We excluded patients who had coronary artery
disease. Informed consent was obtained from all patients and the
study was approved by the Institutional Ethical Review Board of
Strasbourg University.
Human deltoid biopsies
We studied biopsies from deltoid muscles in five patients with
statin-induced myopathy, i.e. patients who developed muscle weakness
and/or rhabdomyolysis while treated with a statin, in whom muscle
weakness and rhabdomyolysis regressed after statin treatment
discontinuation, and in whom other causes of myopathy were
excluded. Muscle biopsy parameters were compared with those
of five untreated normal subjects who volunteered for the study
(Supplementary material online, Table S2). All subjects signed a
consent form approved by the Institutional Review Board of New
Civil Hospital of Strasbourg.
Animal experiments
Experiments were performed on adult male Wistar rats (Depre´,
France) weighing 250–300 g. They housed in neutral temperature
environment (228+28C) on a 12:12 h photoperiod and were pro-
vided food and water ad libitum. Animal procedures were conducted
in accordance with the Declaration of Helsinki and were approved
by our local Ethic Committee.
Atorvastatin (Tahorw) was generously provided by Pfizer and quer-
cetin was kindly provided by C. Damge´ and D. Betbeder (Lille, France).
After 1 week of acclimation, 32 rats were randomly divided into four
groups as followed: (i) animals treated with water (CONT, n ¼ 8);
(ii) animals treated with atorvastatin (ATO, n ¼ 8, 10 mg/kg/day);
(iii) animals treated with quercetin (QUERC, n ¼ 8, 25 mg/kg/day);
and (iv) animals treated with atorvastatin and quercetin (QUERC +
ATO; n ¼ 8; 10 mg/kg/day and 25 mg/kg/day, respectively). Atorvasta-
tin animals were treated with atorvastatin during 2 weeks by oral
gavage and animals treated with quercetin began the treatment 5
days before atorvastatin treatment.
Statistical analysis
Data are presented as mean+ SEM. Statistical analyses were per-
formed using Student’s t-test, one-way repeated measures or
two-way ANOVA followed by a Tukey post test in animal study
(GraphPad Prism 5, Graph Pad Software, Inc., San Diego, CA, USA).
Statistical significance was displayed as *P, 0.05 or **P, 0.01 or
***P, 0.001.
Results
Statins promoted mitochondrial function
and mitochondrial biogenesis in human
cardiac muscle
The patient’s population underwent surgery for valvular aortic ste-
nosis. The clinical characteristics are similar in both groups
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(Supplementary material online, Table S1). We studied different
parameters in atrial muscles of 14 patients treated (n ¼ 6, STAT
group) or not (n ¼ 8, CONT group) with statins. Dihydroethidium
staining showed that ROS content was reduced in the STAT group
(251%, Figure 1A). Peroxisome proliferator-activated receptor
gamma co-activator-1a and PGC-1b mRNA expression levels,
both crucial transcriptional co-activators of numerous genes
coding for mitochondrial proteins, were higher in the STAT
group compared with the CONT group (Figure 1B). Cytosolic
SOD1 and mitochondrial SOD2 mRNA levels were increased in
cardiac muscle of patients treated with statins (Figure 1C).
Maximal oxidative capacities (Vmax) were also increased in these
patients (Figure 1D).
Mitochondrial function and biogenesis
were impaired and reactive oxygen
species production increased in muscle
biopsies of patients with statin-induced
myopathy
We analysed different parameters in deltoid muscles of patients
(n ¼ 5, M-STAT group) suffering from statin-induced myopathy
as well as in age-matched control subjects (n ¼ 5, M-CONT
group). The plasmatic creatine kinase level was significantly
higher in the M-STAT group compared with the M-CONT group
(Supplementary material online, Table S2). Reactive oxygen
species production measured with DHE staining was highly
Figure 1 Exploration of cardiac atrial muscle biopsies from patients treated (STAT group) or not (CONT group) with statins and of human
muscle biopsies from patients with statin myopathy (M-STAT group) compared with control subjects (M-CONT group). (A) Representative
pictures and quantification of reactive oxygen species fluorescence labelled with dihydroethidium. (B) PGC-1a and PGC-1b mRNA expression
levels. (C) SOD1 and SOD2 mRNA expression levels. (D) Maximal mitochondrial respiration measured in the presence of ADP and glutamate/
malate as substrates (Vmax). PGC-1a and -1b, peroxisome proliferator-activated receptor gamma co-activator 1 alpha and beta; SOD1, super-
oxide dismutase 1; SOD2, superoxide dismutase 2. Values were represented as mean+ SEM; n ¼ 5–8 patients in each group, *P, 0.05;
**P, 0.01 with unpaired t-test.
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enhanced in M-STAT patients (Figure 1A). Peroxisome proliferator-
activated receptor gamma co-activator-1a and PGC-1b (Figure 1B)
as well as SOD1 and SOD2 mRNA levels (Figure 1C) were reduced
in biopsies of these patients. Concerning muscular oxidative
capacities, Vmax was largely lower in M-STAT patients (Figure 1D).
Nevertheless, patient’s population differs in term of statin treat-
ment (Supplementary material online, Table S2). Then, in order
to well characterize and to explore the mechanisms responsible
of these alterations, we studied the effects of 2-week atorvastatin
treatment with or without antioxidant treatment in rats.
Atorvastatin decreased total cholesterol
in rats
Total cholesterol decreased by 20% in ATO and QUERC + ATO
groups compared with CONT and QUERC groups (Supplemen-
tary material online, Figure S1A), whereas HDL-cholesterol level
was not significantly different between groups (Supplementary
material online, Figure S1B).
Atorvastatin treatment altered
molecular pathways controlling
mitochondrial biogenesis in muscles and
antioxidant treatment abolished it
We explored the principal factors governing mitochondrial bio-
genesis mechanisms in two muscle types (oxidative cardiac and
glycolytic skeletal muscles) after 2-week treatment with atorvas-
tatin. A co-treatment with antioxidant quercetin was used in
order to demonstrate the role played by ROS production.
Expression of several genes implicated in mitochondrial
biogenesis was analysed by q-RT-PCR (Supplementary material
online, Table S3).
The peroxisome proliferator-activated receptor gamma
co-activator-1a mRNA level was not modified in cardiac muscle
but largely decreased in skeletal muscle after treatment with ator-
vastatin (Figure 2A). Expression of the co-activator PGC-1b mRNA
which is a central factor controlling mitochondrial biogenesis was
largely increased in cardiac muscle but significantly reduced in skel-
etal muscle after atorvastatin treatment (Figure 2B).
Cytochrome oxidase 1 (Cox1) mRNA expression implicated in
mitochondrial metabolism and the nuclear respiratory factor 1
(NRF1) mRNA expression, which is implicated in mitochondrial
biogenesis downstream from PGC-1a and PGC-1b, were both
increased in cardiac muscle but were largely decreased in skeletal
muscle after atorvastatin treatment (Figure 2C and Supplementary
material online, Figure S2). Interestingly, when quercetin treatment
was added to atorvastatin treatment, alterations of all these mRNA
expression levels were abolished.
The relative amount of mitochondria in left ventricle and plan-
taris was determined by real-time PCR. Using Cytochrome b as
the target gene for mtDNA and pyruvate kinase as the internal
control for nuclear DNA, we showed that mtDNA content
increased in cardiac muscle but was decreased in skeletal muscle
after atorvastatin treatment (Figure 2D). Interestingly, when quer-
cetin treatment was added to the atorvastatin treatment, altera-
tions of mtDNA content were abolished.
These data suggested that atorvastatin activated the mechanisms
of mitochondrial biogenesis and increased the mitochondrial mass
in cardiac muscle but reduced mitochondrial biogenesis as well as
mitochondrial mass in glycolytic skeletal muscle. These alterations
Figure 2 Atorvastatin treatment altered molecular pathway of mitochondrial biogenesis in muscles and antioxidant treatment abolished it in
rats. Peroxisome proliferator-activated receptor gamma co-activator-1a (A), peroxisome proliferator-activated receptor gamma
co-activator-1b (B), cytochrome oxidase 1 mRNA expression levels (C ) and relative amount of mtDNA determined by real-time PCR (D)
in cardiac and plantaris muscles. Values were represented as mean+ SEM; n ¼ 8; *P, 0.05; **P, 0.01; ***P, 0.001 between groups with
a two-way ANOVA followed by a Tukey post test.
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Figure 3 Reactive oxygen species were reduced in cardiac muscle of rats after chronic atorvastatin treatment, but were largely increased in
glycolytic one. (A) Total reactive oxygen species production measured by electron paramagnetic resonance in cardiac and plantaris muscles. (B)
Representative pictures and quantification of reactive oxygen species fluorescence labelled with dihydroethidium in cardiac and plantaris
muscles. (C) GSH measurement in cardiac and plantaris muscles. (D) The relative mRNA level of mitochondrial superoxide dismutase2 in
cardiac and plantaris muscles. Values were represented as mean+ SEM; n ¼ 8; *P, 0.05; **P, 0.01; ***P, 0.001 between groups with a
two-way ANOVA followed by a Tukey post test.
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were largely prevented by antioxidant treatment suggesting that
modifications of redox potential could be responsible of the
beneficial as well as deleterious effects of statins. In order to
verify this hypothesis, we first explored the effects of statins as
well as antioxidant treatment on ROS concentration in different
muscle types.
Reactive oxygen species were reduced in
myocardium, but largely increased in
glycolytic skeletal muscle after chronic
atorvastatin treatment
Total ROS production was measured in muscles by electron
paramagnetic resonance (EPR). Interestingly, total ROS production
was reduced in cardiac muscle of rats treated with atorvastatin
and/or quercetin (Figure 3A). On the other hand, in glycolytic plan-
taris muscle treated with statin, total ROS production was
increased and co-treatment with quercetin abolished this effect
(Figure 3A).
The dihydroethidium staining indicated that ROS concentration
was decreased in cardiac muscle treated with atorvastatin and/or
quercetin (Figure 3B). In plantaris muscle, ROS concentration was
increased after statin treatment and this effect was abolished by
antioxidant treatment (Figure 3B).
Antioxidant capacities were improved in
cardiac muscle but importantly reduced
in glycolytic skeletal muscle following
atorvastatin treatment and antioxidant
treatment prevented this reduction
GSH (reduced glutathione) was three-fold higher in cardiac muscle
compared with glycolytic skeletal muscle (Figure 3C). In this skeletal
muscle, atorvastatin reduced GSH content, but co-treatment with
quercetin prevented this deleterious atorvastatin effect (Figure 3C).
The superoxide dismutase (SOD2) mRNA level was increased in
cardiac muscle after both treatments (Figure 3D) but in plantaris
muscle, it decreased by approximately two-fold after atorvastatin
treatment and co-treatment with quercetin prevented these altera-
tions (Figure 3D).
Quercetin protected mitochondrial
respiration of glycolytic muscle against
deleterious effects of atorvastatin in rats
Vmax and Vsucc were neither modified nor by statins nor by querce-
tin treatment or both in cardiac muscle (Figure 4A and B, respect-
ively). In plantaris muscle, Vmax and Vsucc were lower in rats treated
with atorvastatin, and co-treatment with quercetin prevented
these deleterious effects (Figure 4A and B, respectively).
Atorvastatin-activated mitochondrial
biogenesis and protected mitochondria
by a reactive oxygen species-mechanism
in H9C2 cardiomyocytes
To further understand the mechanisms explaining cardiac ben-
eficial effects of atorvastatin, we used a cell culture model. First,
ROS production was evaluated with dihydroethidium staining
method in H9C2 cardiomyocytes after acute exposure with ator-
vastatin (1 mmol/L) during 48 and 72 h. Concerning short-term
exposure (48 h) with atorvastatin, ROS production was enhanced
and when N-AcetylCysteine (NAC) (1 mmol/L), a ROS scavenger,
was added it largely prevented this augmentation (Figure 5A). Per-
oxisome proliferator-activated receptor gamma co-activator-1a,
NRF1, TFAm, and citrate synthase mRNA expression levels were
significantly increased after atorvastatin incubation, and NAC abol-
ished these effects (Figure 5B and Supplementary material online,
Figure S2A–C, respectively).
After 72 h of exposure to atorvastatin (one day later), ROS con-
centration as well as mRNA levels of transcription factors impli-
cated in mitochondrial biogenesis (PGC-1a, NRF1, TFAm)
returned to their normal values. On the other hand, mRNA
expression and protein concentration of SOD2, a key mitochon-
drial antioxidant enzyme regulated by PGC-1a, was largely
increased and co-incubation with NAC abolished these effects.
Altogether, our results suggested that statins initially increased
ROS production, triggering activation of mitochondrial biogenesis
pathways leading to mitochondrial adaptations (i.e. increased of
antioxidant capacities), allowing to reduce the net ROS
production.
Interestingly, we showed that these cellular adaptations follow-
ing atorvastatin exposure at different concentrations (0.5, 1, and
10 mmol/L) protected H9C2 cardiomyocytes from doxorubicin
treatment (Dox 0.5 mmol/L; Figure 5D). Indeed, Dox toxicity was
characterized by a decrease of TMRE fluorescence intensity,
suggesting a loss of mitochondrial membrane potential, and 48 h
Figure 4 Quercetin protected mitochondrial respiration of gly-
colytic muscle against deleterious effects of atorvastatin treat-
ment in rats. Maximal mitochondrial respiration measured in
the presence of ADP and glutamate/malate (Vmax; A) and succi-
nate (Vsucc; B) as substrates in cardiac muscle and plantaris,
respectively. Results were expressed as mean+ SEM; n ¼ 8;
*P, 0.05; **P, 0.01 between groups with a two-way ANOVA
followed by a Tukey post test.
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of atorvastatin pre-treatment at different concentrations prevented
this deleterious effect.
Statin impaired mitochondria by a
reactive oxygen species mechanism in L6
myotubes
The same protocol was realized with skeletal myotubes differen-
tiated from L6 myoblasts and divided in six groups. Control myo-
tubes, myotubes incubated with NAC (1 mmol/L), or atorvastatin
or both, myotubes infected with adenovirus encoding PGC-1a
incubated or not with atorvastatin (1 mmol/L) during 48 h. Acute
atorvastatin treatment largely enhanced ROS production and
when NAC was added to the medium, it largely decreased this
production. Overexpression of PGC-1a in myotubes also abol-
ished ROS augmentation following acute treatment with atorvasta-
tin (Figure 6A). Interestingly, PGC-1a mRNA expression decreased
after atorvastatin incubation, but NAC abolished these alterations
(Figure 6B). As expected, PGC-1a overexpression efficiently
increased PGC-1a mRNA expression (Figure 6B).
Figure 5 Atorvastatin induced expression of peroxisome proliferator-activated receptor gamma co-activator-1a mRNA expression levels by
a mechanism implicating reactive oxygen species production in H9C2 cardiomyocytes. (A) Dihydroethidium staining in H9C2 cardiomyocytes
treated with atorvastatin (1 mmol/L) during 48 and 72 h in the presence or not of antioxidant molecule N-AcetylCysteine (1 mmol/L).
(B) The mRNA expression level of peroxisome proliferator-activated receptor gamma co-activator-1a in different conditions. (C) The
SOD2 mRNA level and protein concentration in different groups. (D) The TMRE-fluorescence intensity level in H9C2 cardiomyocytes
exposed to doxorubicin (0.5 mmol/L) pre-treated or not with atorvastatin at different concentrations (0.5, 1, and 10 mmol/L). Values were rep-
resented as mean+ SEM; n ¼ 4; *P, 0.05; **P, 0.01 atorvastatin condition vs. others groups in the same time incubation with a two-way
ANOVA followed by a Tukey post test.
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In vitro exposure to atorvastatin increased
mitochondrial H2O2 and reactive oxygen
species production lightly in cardiac but
largely in glycolytic fibres of rats
We measured the in vitro capacity of atorvastatin to directly induce
mitochondrial ROS in function of muscle phenotype. During the
H202 measurement, atorvastatin (100 mmol/L) was added in the
presence of muscle fibres from rat cardiac and plantaris muscles.
Interestingly, atorvastatin enhanced mitochondrial H2O2 pro-
duction in cardiac muscle (+53%, Figure 7A), whereas this
production increased robustly in plantaris (+368%, Figure 7C)
with an increase significantly higher in skeletal muscle compared
with myocardium.
By EPR, we also showed that in vitro atorvastatin (100 mmol/L)
enhanced total ROS production more in plantaris (+93%;
Figure 7D) than in cardiac muscle (+67%; Figure 7B).
Discussion
This study provides two major findings: (i) in human as well as in
rat, statins triggered transcriptional activation of mitochondrial bio-
genesis in myocardium (increase of PGC-1a and -b expression
levels) as well as antioxidant capacities via a mechanism implicating
ROS signalling pathway, (ii) in skeletal muscle of patients with
statin-induced myopathy as well as in rat skeletal muscle with
low antioxidant capacities, these molecules induced high-oxidative
stress, responsible of transcriptional deactivation of mitochondrial
biogenesis as well as mitochondrial dysfunctions. Altogether, we
showed that statins increased ROS production differently in
heart and skeletal muscle and could be represent as a double-
edged sword: they are beneficial by playing an important role in
cell signalling involved in antioxidant defence network in cardiac
muscle, but could be harmful by inducing excessive oxidative
stress in vulnerable skeletal muscle.21 We proposed that activation
of PGC-1 expression could be triggered by low doses of mito-
chondrial ROS generation following atorvastatin treatment, in
order to counteract stressor challenges and hence re-establish
homeostasis. This phenomenon was called mitochondrial hormesis
or ‘mitohormesis’.13,20 Our data suggested that statins could act
through this mitohormesis mechanism.
With atrial tissues obtained during coronary bypass surgery of
patients treated or not with statins, we studied the mitochondrial
respiration in skinned atrial fibres.22 Interestingly, maximal mito-
chondrial respiration as well as genes expression of antioxidant
enzymes and factors controlling mitochondrial biogenesis was
higher in myocardium of treated patients. In particular, our
results showed in human cardiac muscle that statins treatment acti-
vated PGC1-a and -b which were considered as the major regula-
tors of several crucial aspects of energy metabolism.23,24 By
increasing these central factors, statins could strengthen human
cardiac muscle defence against metabolic stress by improving anti-
oxidant defence, which seems to be the case since expression of
SOD1 and SOD2 were higher in atrium of patients treated with
statins. However, in deltoid biopsies of patients with statin-induced
myopathy, mitochondrial function was impaired together with an
abnormally high induction of ROS production. In addition,
PGC-1a and PGC-1b mRNA expressions were down-regulated
suggesting deactivation of mitochondrial biogenesis signalling
pathway. Nevertheless, patient’s population differs in term of
statin treatment and treatment associated with statins (Supplemen-
tary material online, Table S1).These results are in accordance with
some studies showing that skeletal muscle mitochondria are
impaired after statins treatment or in acute conditions7,9 and give
a molecular details of these muscular abnormalities. Sirvent
et al.7 showed that simvastatin-induced mitochondrial impairment
resulting from inhibition of the respiratory chain complex I in
human skeletal muscle. Concerning genes expression, a recent
study showed in skeletal muscle from statin-treated but non-
myopathic patients, that expression of genes responsible for mito-
chondrial function was unaffected, suggesting that regulation of
Figure 6 Atorvastatin decreased peroxisome proliferator-
activated receptor gamma co-activator-1a mRNA expression
levels due to the increase of reactive oxygen species level in L6
Woody myotubes. L6 myotubes were infected or not with ade-
novirus encoding peroxisome proliferator-activated receptor
gamma co-activator-1a and were treated or not with atorvastatin
(1 mmol/L) as well as of N-AcetylCysteine (1 mmol/L). We
measured (A) Dihydroethidium staining, and (B) peroxisome
proliferator-activated receptor gamma co-activator-1a mRNA
expression in the different groups. Values were represented as
mean+ SEM; n ¼ 3; *P, 0.05 compared with all others con-
ditions; **P, 0.01 compared with all other conditions with a
one-way ANOVA followed by a Dunett post test.
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mitochondrial biogenesis was specifically impaired in skeletal
muscle of patients with statin-induced myopathy.25
In order to clearly demonstrate and explain why and how statins
could induce opposite effects in muscles with different phenotypes
(i.e. cardiac vs. skeletal muscle), we carried out several exper-
iments with animal and cell models. In particular, we studied the
role played by muscular ROS production as well as the role
played by co-factors PGC-1a and PGC-1b in the mechanisms of
muscular mitochondrial adaptations and impairments following
statin treatment.
In cardiac muscle of rats, chronic treatment with atorvastatin
activated PGC-1b expression more that PGC-1a, improved anti-
oxidant capacities and decreased cellular ROS concentration, con-
firming the effects observed in human patients treated with statins.
Our results suggested that in rat, statins changed the constitutive
mitochondrial biogenesis level in order to change qualitatively
more than quantitatively the mitochondrial properties, particularly
for improving mitochondrial ROS-detoxifying capacities. Because
of the volume occupied by mitochondria in rat cardiomyocytes
(30% in adult) and the extremely low cytosolic volume (4–
7%), it is clear that the increase of mitochondrial mass will auto-
matically be at the expense of myofibrillar volume, thus compro-
mising contractile function.19 Consequently, increase of
mitochondrial mass will be low and strictly controlled in adult
heart of rats. On the other hand, in human, the metabolic rate
was considerably lower than in rat and it seems to be possible
to enlarge the mitochondrial mass. Then, we can speculate that
in human, an increase of both PGC-1a and b was necessary in
order to highly improve quantitatively as well as qualitatively the
mitochondrial function in myocardium (i.e. an increase of
mitochondrial volume as well as antioxidant capacities). In rats,
we can postulate that activation of PGC-1b expression, which is
known to preferentially induce genes involved in the removal of
ROS,26,27 is essential in order to improve mitochondrial ROS-
detoxifying capacities of the myocardium and to slightly increase
mitochondrial mass.
Interestingly, when cardiomyocytes in culture or permeabilized
cardiac fibres were acutely exposed to atorvastatin, it induced an
increase of mitochondrial ROS production, whereas after 3 days
in culture or 2-week treatment in rats, statins increased SOD2
protein concentration and reduced basal ROS concentration in
cardiac muscle. These results suggest that it’s the initial augmenta-
tion of ROS production following statins treatment which could
trigger the improvement of antioxidant capacities and mitochon-
drial function allowing to reduced the basal ROS concentration
in the following weeks. In order to verify these hypothesize, we
used an antioxidant molecule in addition to atorvastatin treatment
and tested it in our in vivo and in vitro models (quercetin and NAC
treatments, respectively). We found that these treatments, by
reducing the initial augmentation of ROS, prevented the enhance-
ment of PGC1 expression as well as mRNA expression of antiox-
idant enzymes in cardiac cells. Altogether, we found that
atorvastatin increased ROS production which initiated expression
of PGC-1a and -b, leading to mitochondrial biogenesis and the
augmentation of oxidative capacities in cardiac muscle. We can
speculate that statins, by a PGC-1s dependant-mechanism, could
play a key role in the ROS homeostatic cycle in cardiac muscle.
Next step was to determine whether atorvastatin treatment
were able to protect cardiomyocytes from a chemical stress.
Toxic effects of doxorubicin were explored in cardiomyocytes.
Figure 7 In vitro atorvastatin increased slightly reactive oxygen species production in cardiac muscle, whereas it highly increased in plantaris
muscle. Mitochondrial H2O2 emission in permeabilized fibres and total reactive oxygen species production measured by electron paramagnetic
resonance were evaluated in cardiac (A and B, respectively) and plantaris muscles (C and D, respectively) after addition of 100 mmol/L atorvas-
tatin. Values represented in percentage of control; n ¼ 7–10, *P, 0.05, and ***P, 0.001 vs. control with paired t-test.
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Our results showed that atorvastatin incubation prevented mito-
chondrial cardiotoxicity by reducing the loss of mitochondrial
membrane potential and by inducing mitochondrial biogenesis
pathways. This is in accordance with studies showing that statins
have antioxidant properties28 and attenuated mitochondrial mem-
brane depolarization after exposure to oxidative stress in cardiac
myocytes.6 Then, statins treatment, by inducing mitochondrial
adaptations, reduced metabolic toxic effects of this molecule fre-
quently used in clinical setting.
In glycolytic skeletal muscle with low glutathione content,
statins robustly increased production of mitochondrial ROS in
vitro as well as in vivo confirming the effects observed in deltoid
biopsies of patients with statin-induced myopathy. These results
and the fact that antioxidant treatments prevented skeletal
muscle from deleterious effects of statins, suggested that high-
oxidative stress could be the triggering factor inducing mitochon-
drial dysfunction and down-regulation of mitochondrial biogenesis
mechanisms. Moreover, when PGC-1a was overexpressed in L6
myotubes, ROS production was decreased and deleterious
effects were prevented, showing the central role played by this
transcriptional co-factor in order to prevent deleterious effect
of statins. Interestingly, the fact that quercetin treatment which
is a powerful and natural antioxidant molecule,29 protect mito-
chondria of skeletal muscle in animals, suggest that it is possible
to find therapeutical strategies consisting of reducing oxidative
stress in skeletal muscle of patients with statin-associated
myopathy.
In conclusion, our study clarifies contradictory studies from the
literature showing beneficial effects of statins in cardiac muscle
while several studies demonstrated deleterious effects in skeletal
muscle.8 Our results suggest that statins acted through a ‘mito-
hormesis mechanism’ and protected cardiac muscles, by stimulat-
ing mitochondrial biogenesis and antioxidant defence through
ROS-induced PGC-1 family expression (Figure 8). Conversely,
when ROS-detoxifying constituents were not sufficient to
decrease the initial statin induced ROS production, as in skeletal
muscle of rat and in deltoid muscle of some patients, statins
could be toxic for mitochondria but an adequate antioxidant
therapy should prevent these muscular impairments.
Supplementary material
Supplementary material is available at European Heart Journal
online.
Figure 8 Scheme illustrating the action of statins on mitochondrial function according to muscular phenotype. Statins acted through a
‘mitohormesis mechanism’ and protected oxidative cardiac muscle, by stimulating the mitochondrial biogenesis through mild oxidative stress
and improved metabolic health. Conversely, when reactive oxygen species-detoxifying constituents were not sufficient to decrease the
initial statin induced high-oxidative stress in glycolytic skeletal muscle, they induced mitochondrial dysfunctions, down-regulation of mitochon-
drial biogenesis and muscular pains or myopathy.
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